TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26265447

Group type: EXPERIMENTAL
Intervention: CryoSeal® (5 ml per ITA bed)
Number of subjects: 1445

Group type: COMPARATOR
Intervention: No CryoSeal® (control)
Number of subjects: 1445
Study: 23073671

Group type: EXPERIMENTAL
Intervention: EHR prompt for HBV testing
Number of subjects: 175

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 175
Study: 20941948

Group type: EXPERIMENTAL
Intervention: Chitosan-containing spray (1% concentration, low molecular chitosan, degree of deacetylation 87%)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Chitosan-free control (vehicle only) spray
Number of subjects: 29
Study: 18371465

Group type: EXPERIMENTAL
Intervention: MC-1 (250 mg/d)
Number of subjects: 3023

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3023
Study: 16298234

Group type: EXPERIMENTAL
Intervention: Alzheimer disease patients
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Vascular dementia and dementia of mixed type patients
Number of subjects: 218

Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Non‐Alzheimer forms of dementia and other neurodegenerative diseases
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 218
Study: 14750576

Group type: EXPERIMENTAL
Intervention: Prednisolone treatment starting at 40 mg/day, tapered by 5 mg every 2 weeks for 16 weeks
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 10497377

Group type: EXPERIMENTAL
Intervention: Leukostop filter
Number of subjects: 15

Group type: COMPARATOR
Intervention: Blood transfusion without filter
Number of subjects: 15

Group type: COMPARATOR
Intervention: Blood transfusion with filter
Number of subjects: 15
Study: 8766365

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy during psychotherapy stages
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of pharmacotherapy and psychotherapy
Number of subjects: 0
Study: 2012511

Group type: EXPERIMENTAL
Intervention: Prednisone 0.3 mg/kg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Prednisone 0.75 mg/kg
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 6802095

Group type: EXPERIMENTAL
Intervention: 15 mmole of sodium phosphate at the fourth hour
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 15 mmole of sodium phosphate at 2, 6, and 10 hours
Number of subjects: 44

Group type: COMPARATOR
Intervention: No phosphate replacement
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Phosphate therapy
Number of subjects: 44
Study: 31401672

Group type: EXPERIMENTAL
Intervention: Intracoronary autologous bone marrow cell (BMC) transfer
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Overall patient cohort (both BMC and placebo)
Number of subjects: 51
Study: 29574170

Group type: EXPERIMENTAL
Intervention: Educational program with instructions for performing 'the Knack' (n=50)
Number of subjects: 99

Group type: COMPARATOR
Intervention: No intervention (Control group, n=49)
Number of subjects: 99
Study: 27341675

Group type: EXPERIMENTAL
Intervention: Guided Imagery and Progressive Muscle Relaxation
Number of subjects: 208

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 208
Study: 23906509

Group type: EXPERIMENTAL
Intervention: Verbal worry
Number of subjects: 50

Group type: COMPARATOR
Intervention: Imagery‐based worry
Number of subjects: 50
Study: 22250666

Group type: EXPERIMENTAL
Intervention: Self-management education program (SM), 4-week intervention based on 'Living Well with COPD' program.
Number of subjects: 110

Group type: COMPARATOR
Intervention: Usual care (UC), n = 50.
Number of subjects: 110
Study: 20413602

Group type: EXPERIMENTAL
Intervention: Gene-expression profiling
Number of subjects: 602

Group type: COMPARATOR
Intervention: Routine endomyocardial biopsies
Number of subjects: 602
Study: 18779280

Group type: EXPERIMENTAL
Intervention: 2 servings/d of a pistachio diet (2 PD)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 1 serving/d of a pistachio diet (1 PD)
Number of subjects: 28

Group type: COMPARATOR
Intervention: lower‐fat control diet with no pistachios
Number of subjects: 28
Study: 15714351

Group type: EXPERIMENTAL
Intervention: Supervised physical training for three months including back school
Number of subjects: 183

Group type: COMPARATOR
Intervention: Back school (comparison group)
Number of subjects: 183
Study: 12351551

Group type: EXPERIMENTAL
Intervention: Monoculture medium (Rotterdam medium) for 5 days
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Rotterdam medium for 3 days followed by fresh Rotterdam medium for 2 days
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: G1/G2 sequential culture system for 5 days
Number of subjects: 158
Study: 10075143

Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine
Number of subjects: 537

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 537
Study: 7669385

Group type: EXPERIMENTAL
Intervention: DTP vaccine (batch 1)
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: DTP vaccine (batches 2 and 3)
Number of subjects: 531
Study: 2187694

Group type: EXPERIMENTAL
Intervention: Comprehensive rehabilitation program
Number of subjects: 119

Group type: COMPARATOR
Intervention: Education control program
Number of subjects: 119
Study: 7362083

Group type: EXPERIMENTAL
Intervention: Fenoterol hydrobromide (Berotec) 0.1% solution, 60 micrograms per nostril every six hours
Number of subjects: 25

Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fenoterol hydrobromide (Berotec) 0.1% solution, doubled dosage
Number of subjects: 25
Study: 6341684

Group type: EXPERIMENTAL
Intervention: Chlorthalidone, 100 mg/day for 6 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 30357394

Group type: EXPERIMENTAL
Intervention: TRC105 and pazopanib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pazopanib alone
Number of subjects: 0
Study: 29912604

Group type: EXPERIMENTAL
Intervention: DHA supplementation (2000 mg/day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: DHA supplementation
Number of subjects: 11
Study: 27741174

Group type: EXPERIMENTAL
Intervention: Enoxaparin plus Aspirin (4,000 IU enoxaparin + 100 mg aspirin)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Aspirin alone (100 mg aspirin)
Number of subjects: 232
Study: 25474427

Group type: EXPERIMENTAL
Intervention: 100 mg indomethacin
Number of subjects: 576

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy (ASA)
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: No antiplatelet therapy (non-ASA)
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: No clopidogrel (non-clopidogrel)
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Indomethacin and placebo
Number of subjects: 576
Study: 22627795

Group type: EXPERIMENTAL
Intervention: CTP (CT perfusion) group
Number of subjects: 36

Group type: COMPARATOR
Intervention: Stroke scale group (NIHSS with NCCT and CTA)
Number of subjects: 36
Study: 21041921

Group type: EXPERIMENTAL
Intervention: etravirine 200 mg twice daily
Number of subjects: 1203

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1203
Study: 18581020

Group type: EXPERIMENTAL
Intervention: Fast-track group (continuous infusion of fentanyl and propofol, atracurium one hour later)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional extubation group (bolus doses of fentanyl and pancuronium)
Number of subjects: 100
Study: 15858063

Group type: EXPERIMENTAL
Intervention: Yohimbine (selective alpha2‐adrenoceptor antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11798991

Group type: EXPERIMENTAL
Intervention: Throwing group (professional pitchers)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nonthrowing group (control)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Comparison of dominant shoulders
Number of subjects: 50
Study: 10527088

Group type: EXPERIMENTAL
Intervention: Multidisciplinary training program for rheumatoid arthritis
Number of subjects: 68
Study: 7697926

Group type: EXPERIMENTAL
Intervention: gp120-depleted, inactivated HIV-1 antigen in incomplete Freund's adjuvant (IFA; HIV-1 Immunogen)
Number of subjects: 0

Group type: COMPARATOR
Intervention: IFA alone
Number of subjects: 0
Study: 2014355

Group type: EXPERIMENTAL
Intervention: Portable method for theophylline measurement
Number of subjects: 69

Group type: COMPARATOR
Intervention: Conventional laboratory-based analysis
Number of subjects: 69
Study: 7018051

Group type: EXPERIMENTAL
Intervention: Cinoxacin 250 mg four times a day (QID)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Cinoxacin 500 mg twice a day (BID)
Number of subjects: 91
Study: 30182128

Group type: EXPERIMENTAL
Intervention: Patient self-reporting of FIM motor score
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Patient self-reporting of individual motor items
Number of subjects: 33

Group type: COMPARATOR
Intervention: Multidisciplinary assessment of FIM motor score
Number of subjects: 33
Study: 28342227

Group type: EXPERIMENTAL
Intervention: PVP-I 1.0% and dexamethasone 0.1%
Number of subjects: 78

Group type: COMPARATOR
Intervention: Dexamethasone 0.1%
Number of subjects: 78

Group type: COMPARATOR
Intervention: Lubricating eyedrops (hypromellose 0.3%)
Number of subjects: 78
Study: 25904734

Group type: EXPERIMENTAL
Intervention: Health Committee (HC) group
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study: 23269120

Group type: EXPERIMENTAL
Intervention: SGA infants
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Lower mean birth weight z-score
Number of subjects: 367
Study: 21749850

Group type: EXPERIMENTAL
Intervention: Water infusion
Number of subjects: 116

Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 116
Study: 18270378

Group type: EXPERIMENTAL
Intervention: Cutting balloon angioplasty (CBA)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conventional percutaneous transluminal angioplasty (PTA)
Number of subjects: 43

Group type: COMPARATOR
Intervention: PTA
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: CBA
Number of subjects: 43
Study: 16527031

Group type: EXPERIMENTAL
Intervention: Zafirlukast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loratadine and pseudoephedrine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 12883303

Group type: EXPERIMENTAL
Intervention: Olive oil emulsion
Number of subjects: 45

Group type: COMPARATOR
Intervention: Soybean oil emulsion
Number of subjects: 45
Study: 11044477

Group type: EXPERIMENTAL
Intervention: Succimer
Number of subjects: 780

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 780
Study: 9325952

Group type: EXPERIMENTAL
Intervention: Replacement mattress
Number of subjects: 0

Group type: COMPARATOR
Intervention: Static air mattress
Number of subjects: 0
Study: 8238122

Group type: EXPERIMENTAL
Intervention: 100 IU of oxytocin in 20 ml of normal saline solution
Number of subjects: 50

Group type: COMPARATOR
Intervention: 20 ml of normal saline solution (placebo)
Number of subjects: 50
Study: 3321878

Group type: EXPERIMENTAL
Intervention: carteolol 1%
Number of subjects: 20

Group type: COMPARATOR
Intervention: carteolol 2%
Number of subjects: 20
Study: 29653645

Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 2203

Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 2203
Study: 28401136

Group type: EXPERIMENTAL
Intervention: Community pharmacy-based case finding and intervention
Number of subjects: 48
Study: 26609282

Group type: EXPERIMENTAL
Intervention: Ashwagandha (300 mg twice daily)
Number of subjects: 57
Study: 24023317

Group type: EXPERIMENTAL
Intervention: Combined androgen blockade with zoledronic acid (CAB-ZA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Combined androgen blockade (CAB)
Number of subjects: 60
Study: 21149436

Group type: EXPERIMENTAL
Intervention: High-sugar cereals
Number of subjects: 91

Group type: COMPARATOR
Intervention: Low-sugar cereals
Number of subjects: 91
Study: 18328090

Group type: EXPERIMENTAL
Intervention: Lumiracoxib 100 mg once daily
Number of subjects: 3032

Group type: EXPERIMENTAL
Intervention: Lumiracoxib 100 mg twice daily
Number of subjects: 3032

Group type: COMPARATOR
Intervention: Celecoxib 200 mg once daily
Number of subjects: 3032
Study: 16888080

Group type: EXPERIMENTAL
Intervention: SHiDo chemotherapy
Number of subjects: 129

Group type: COMPARATOR
Intervention: CHOP chemotherapy
Number of subjects: 129
Study: 12741348

Group type: EXPERIMENTAL
Intervention: Menotropin treatment for three months (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Menotropin treatment starting three months after surgery (Group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Varicocelectomy only (Group C)
Number of subjects: 60
Study: 10971538

Group type: EXPERIMENTAL
Intervention: Laser assisted uvulopalatoplasty (LAUP)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Conventional uvulopalatopharyngoplasty (UPPP)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Comparison of LAUP and UPPP
Number of subjects: 47
Study: 8835649

Group type: EXPERIMENTAL
Intervention: Brofaromine or fluvoxamine (intervention)
Number of subjects: 30

Group type: COMPARATOR
Intervention: N/A (control group not specified)
Number of subjects: 30
Study: 1411848

Group type: EXPERIMENTAL
Intervention: Single-day split dose of 1.6 g of metronidazole
Number of subjects: 132

Group type: COMPARATOR
Intervention: Single 2-g dose of tinidazole
Number of subjects: 132
Study: 3907725

Group type: EXPERIMENTAL
Intervention: Meditation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Positive expectations of meditation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 40
Study: 30937447

Group type: EXPERIMENTAL
Intervention: Short pre-travel consultation (8-12 minutes) with smartphone support
Number of subjects: 149

Group type: COMPARATOR
Intervention: Standard length pre-travel consultation (18-22 minutes)
Number of subjects: 149
Study: 29106665

Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks (NIVO3)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nivolumab 1 mg/kg + ipilimumab 3 mg/kg every 3 weeks for 4 doses (NIVO1+IPI3)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg + ipilimumab 1 mg/kg every 3 weeks for 4 doses (NIVO3+IPI1)
Number of subjects: 40
Study: 26911520

Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning (RIC) + primary percutaneous coronary intervention (pPCI)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Primary percutaneous coronary intervention (pPCI) alone
Number of subjects: 129
Study: 24673834

Group type: EXPERIMENTAL
Intervention: Accelerometer-determined physical activity (PA)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Self-reported health
Number of subjects: 560
Study: 23001752

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 44
Study: 20705290

Group type: EXPERIMENTAL
Intervention: 1-day mifepristone and misoprostol regimen
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 2-day mifepristone and misoprostol regimen
Number of subjects: 100
Study: 18263997

Group type: EXPERIMENTAL
Intervention: Breast health messages administered by salon stylists
Number of subjects: 1210

Group type: COMPARATOR
Intervention: Control salons (no messages)
Number of subjects: 1210
Study: 16080872

Group type: EXPERIMENTAL
Intervention: Triptorelin (3.75 mg injected intramuscularly every 28 days for 3 months)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Leuprorelin (3.75 mg injected subcutaneously every 28 days for 3 months)
Number of subjects: 125
Study: 12435290

Group type: EXPERIMENTAL
Intervention: CVAP + docetaxel (100 mg/m2)
Number of subjects: 162
Study: 10355669

Group type: EXPERIMENTAL
Intervention: Subdural electrodes made of platinum
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Scalp recording
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Seizure control after resection of the cortex
Number of subjects: 9
Study: 7577853

Group type: EXPERIMENTAL
Intervention: 600 mg danazol daily (n = 17)
Number of subjects: 36

Group type: COMPARATOR
Intervention: 2.5 mg gestrinone twice weekly (n = 19)
Number of subjects: 36
Study: 7682931

Group type: EXPERIMENTAL
Intervention: Scopolamine (0.25‐0.75 mg, intramuscular)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Scopolamine (0.50 and 0.75 mg, intramuscular)
Number of subjects: 8
Study: 2947098

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29996980

Group type: EXPERIMENTAL
Intervention: PRPFM treatment group
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: PRPFM technique
Number of subjects: 76

Group type: COMPARATOR
Intervention: Double-row technique (control)
Number of subjects: 76
Study: 26086792

Group type: EXPERIMENTAL
Intervention: Prolonged-release melatonin 2 mg daily
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 24296517

Group type: EXPERIMENTAL
Intervention: High-dose calcium lactate (300 mg · kg(‐1) body mass)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Low-dose calcium lactate (150 mg · kg(‐1) body mass)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 22728514

Group type: EXPERIMENTAL
Intervention: Infusion of intestinal microbiota from lean donors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Autologous microbiota infusion
Number of subjects: 0
Study: 20508469

Group type: EXPERIMENTAL
Intervention: Thermogenic drink (TD) - 336 mL daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (PLA) - 336 mL daily
Number of subjects: 60
Study: 18232610

Group type: EXPERIMENTAL
Intervention: Use of Personal Digital Assistants (PDAs) during clinical education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified what intervention was used)
Number of subjects: 0
Study: 16405713

Group type: EXPERIMENTAL
Intervention: tTG-based ELISA
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: eTG-based ELISA
Number of subjects: 204
Study: 12627313

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (3 x 500 mg tablets daily for 7 days prior to race and 150 mg/l in carbohydrate beverages during race)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (3 tablets daily for 7 days prior to race and no vitamin C in carbohydrate beverages during race)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups (Vitamin C and Placebo)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation
Number of subjects: 28
Study: 9666526

Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (Praxilene)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 8291920

Group type: EXPERIMENTAL
Intervention: Granisetron (40 micrograms/kg)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Granisetron plus MPL (10 mg/kg)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Granisetron alone
Number of subjects: 107

Group type: COMPARATOR
Intervention: Granisetron plus MPL
Number of subjects: 107
Study: 3174217

Group type: EXPERIMENTAL
Intervention: Stryker Constavac
Number of subjects: 45

Group type: COMPARATOR
Intervention: Snyder Hemovac
Number of subjects: 45
Study: 5787671

Group type: EXPERIMENTAL
Intervention: LB46, 0.5 mg by oral administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol, 20 mg
Number of subjects: 0
Study: 29467598

Group type: EXPERIMENTAL
Intervention: Spirulina extract (1500 mg for 6 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 29122251

Group type: EXPERIMENTAL
Intervention: Acupressure at LI4 and HT7 points
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham pressure
Number of subjects: 90

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 90
Study: 26595965

Group type: EXPERIMENTAL
Intervention: Intravenous laser irradiation in addition to traditional medicamental therapy (Group 2)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Laser skin treatment (Group 3)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Traditional medicamental therapy alone (Control Group 1)
Number of subjects: 120
Study: 23307840

Group type: EXPERIMENTAL
Intervention: FLF24 (24 h fermented liquid feed)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: FLF48 (48 h fermented liquid feed)
Number of subjects: 240

Group type: COMPARATOR
Intervention: CON (dry basal feed)
Number of subjects: 240
Study: 21178603

Group type: EXPERIMENTAL
Intervention: Pregabalin (n=80)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo (n=77)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study: 18477182

Group type: EXPERIMENTAL
Intervention: High fat meal (3.1 MJ, 742 kcal, 75.8% fat)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: High carbohydrate meal (3.3 MJ, 794 kcal, 77.5% carbohydrate)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Dietetic advice
Number of subjects: 5
Study: 17070147

Group type: EXPERIMENTAL
Intervention: Aggressive LDL-C reduction (goal <70 mg/dL)
Number of subjects: 549

Group type: COMPARATOR
Intervention: Standard LDL-C reduction (goal <100 mg/dL)
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Aggressive BP reduction (goal <115/75 mm Hg)
Number of subjects: 549

Group type: COMPARATOR
Intervention: Standard BP reduction (goal <130/85 mm Hg)
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Secondary end points include carotid plaque score, left ventricular geometry and function, serum C-reactive protein, and safety measures.
Number of subjects: 549
Study: 13677262

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (BMT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined immunosuppressive treatment (antithymocyte globulin, methylprednisolone, and cyclosporine)
Number of subjects: 0
Study: 10862065

Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine 0.1 mmol/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine 0.2 mmol/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine
Number of subjects: 30